Retention on antiretroviral therapy in person with HIV and viral hepatitis coinfection in Ethiopia: a retrospective cohort study.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
04 04 2022
Historique:
received: 28 04 2021
accepted: 21 03 2022
entrez: 5 4 2022
pubmed: 6 4 2022
medline: 7 4 2022
Statut: epublish

Résumé

HIV coinfection with viral hepatitis B (HBV) or viral hepatitis C (HCV) is not uncommon in Ethiopia. Although the coinfections are presumed to interfere with antiretroviral treatment (ART), this is not widely studied in Sub-Saharan African settings. This study was conducted to determine ART retention in persons coinfected with HIV + HBV or HIV + HCV. We reviewed the medical records of HIV-positive adults who initiated ART between 2011 to 2018 in four high-burden hospitals of Addis Ababa. Retention in care was the primary outcome of the study, which was compared between HIV and either HBV or HCV coinfected persons, and HIV-monoinfected persons. A parametric Gompertz regression model was used to compare retention between the coinfected and monoinfected groups. A total of 132 coinfected persons and 514 HIV-monoinfected individuals who initiated ART in 2011-2018 were compared. At 12-months of follow-up, 81.06% [95% CI: 73.3-86.9%] of the coinfected and 86.96% [95% CI: 83.7-89.6%] of the monoinfected were still on ART care. Cumulative retention in the coinfected group was 68.93% [60.4-76.3%] versus 80.35% [76.6-83.5%, p = 0.0048] in the monoinfected group. The cumulative retention was lower (61.25, 95% CI: 49.9-71.4%) in male coinfected patients than male monoinfected patients (77.77, 95% CI: 71.8-82.7%, p = 0.0041). In contrast, cumulative retention was similar in females in the coinfected group (80.76, 95% CI:67.3-89.5%) versus the monoinfected group (82.29, 95% CI:77.4-86.3%, p = 0.792). Overall, HIV-positive with viral hepatitis coinfection were 24 and 31% less likely to still be on ART care than the monoinfected group at 12 months and overall, with sub-distribution adjusted hazard ratio (AHR) of 0.76(95% CI:0.61-0.96, p = 0.021) and 0.69(95% CI:0.54-0.87, p = 0.002) respectively. We observed that coinfected individuals are less likely to stay on ART than HIV monoinfected individuals. The low retention in the coinfected group from this study may affect the success of survival gained in people living with HIV (PLHIV) in the long term. More concerted efforts need to be made to retain coinfected individuals at least at the level of monoinfected persons on long-term ART care. Future studies are needed to better understand the difference in retention, preferable in a prospective manner.

Sections du résumé

BACKGROUND
HIV coinfection with viral hepatitis B (HBV) or viral hepatitis C (HCV) is not uncommon in Ethiopia. Although the coinfections are presumed to interfere with antiretroviral treatment (ART), this is not widely studied in Sub-Saharan African settings. This study was conducted to determine ART retention in persons coinfected with HIV + HBV or HIV + HCV.
METHODS
We reviewed the medical records of HIV-positive adults who initiated ART between 2011 to 2018 in four high-burden hospitals of Addis Ababa. Retention in care was the primary outcome of the study, which was compared between HIV and either HBV or HCV coinfected persons, and HIV-monoinfected persons. A parametric Gompertz regression model was used to compare retention between the coinfected and monoinfected groups.
RESULTS
A total of 132 coinfected persons and 514 HIV-monoinfected individuals who initiated ART in 2011-2018 were compared. At 12-months of follow-up, 81.06% [95% CI: 73.3-86.9%] of the coinfected and 86.96% [95% CI: 83.7-89.6%] of the monoinfected were still on ART care. Cumulative retention in the coinfected group was 68.93% [60.4-76.3%] versus 80.35% [76.6-83.5%, p = 0.0048] in the monoinfected group. The cumulative retention was lower (61.25, 95% CI: 49.9-71.4%) in male coinfected patients than male monoinfected patients (77.77, 95% CI: 71.8-82.7%, p = 0.0041). In contrast, cumulative retention was similar in females in the coinfected group (80.76, 95% CI:67.3-89.5%) versus the monoinfected group (82.29, 95% CI:77.4-86.3%, p = 0.792). Overall, HIV-positive with viral hepatitis coinfection were 24 and 31% less likely to still be on ART care than the monoinfected group at 12 months and overall, with sub-distribution adjusted hazard ratio (AHR) of 0.76(95% CI:0.61-0.96, p = 0.021) and 0.69(95% CI:0.54-0.87, p = 0.002) respectively.
CONCLUSIONS
We observed that coinfected individuals are less likely to stay on ART than HIV monoinfected individuals. The low retention in the coinfected group from this study may affect the success of survival gained in people living with HIV (PLHIV) in the long term. More concerted efforts need to be made to retain coinfected individuals at least at the level of monoinfected persons on long-term ART care. Future studies are needed to better understand the difference in retention, preferable in a prospective manner.

Identifiants

pubmed: 35379215
doi: 10.1186/s12889-022-13025-y
pii: 10.1186/s12889-022-13025-y
pmc: PMC8978407
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

644

Informations de copyright

© 2022. The Author(s).

Références

AIDS. 2017 Nov 28;31(18):2525-2532
pubmed: 28926400
Virol J. 2013 May 30;10:171
pubmed: 23721493
BMC Immunol. 2013 May 17;14:23
pubmed: 23679118
PLoS One. 2013;8(3):e59197
pubmed: 23527132
PLoS One. 2016 Mar 02;11(3):e0150512
pubmed: 26933963
Antivir Ther. 2016;21(5):385-96
pubmed: 26731316
AIDS. 2014 May 15;28(8):1181-91
pubmed: 24901259
Proc Natl Acad Sci U S A. 1987 Mar;84(5):1187-91
pubmed: 3469661
Asian Pac J Cancer Prev. ;18(4):981-985
pubmed: 28545196
PLoS One. 2014 Feb 12;9(2):e88552
pubmed: 24533106
BMC Infect Dis. 2016 Dec 19;16(1):761
pubmed: 27993129
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
PLoS Med. 2007 Oct 16;4(10):e298
pubmed: 17941716
J Viral Hepat. 2020 Mar;27(3):294-315
pubmed: 31603999
Cancer Res. 1993 Feb 15;53(4):790-4
pubmed: 8381328
BMC Infect Dis. 2019 Oct 29;19(1):917
pubmed: 31664923
AIDS. 2017 Sep 24;31(15):2035-2052
pubmed: 28692539
AIDS. 2009 Sep 10;23(14):1881-9
pubmed: 19550291
J AIDS Clin Res. 2013 Jun 29;Suppl 3:
pubmed: 25328814
BMC Infect Dis. 2020 Jun 22;20(1):439
pubmed: 32571232
Eur Rev Med Pharmacol Sci. 2012 Oct;16(11):1473-83
pubmed: 23111959
J Int AIDS Soc. 2016 Mar 14;19(1):20659
pubmed: 26979535
Clin Infect Dis. 2018 Nov 13;67(11):1643-1652
pubmed: 29889240
PLoS One. 2015 Jun 26;10(6):e0130649
pubmed: 26114436
Int J Cancer. 2010 Aug 1;127(3):499-504
pubmed: 20201099

Auteurs

Eleni Seyoum (E)

Institute of Public Health, University of Gondar, Gondar, Ethiopia & Department of Epidemiology and Biostatistics, Addis Continental Institute of Public Health, 10433, Addis Ababa, Ethiopia. Eleniseyoum45@gmail.com.

Meaza Demissie (M)

Department of Epidemiology and Biostatistics, Addis Continental Institute of Public Health, Addis Ababa, Ethiopia.

Alemayehu Worku (A)

School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Adane Mihret (A)

Armauer Hansen Research Institute, Addis Ababa, Ethiopia.

Alemseged Abdissa (A)

Armauer Hansen Research Institute, Addis Ababa, Ethiopia.

Yemane Berhane (Y)

Department of Epidemiology and Biostatistics, Addis Continental Institute of Public Health, Addis Ababa, Ethiopia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH